Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.98 |
| ▸ | POLB | P06746 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 4/20 | 0.43 |
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30433668 | 1.00 | KCNH2 (1.00) | KCNH2CYP3A4CYP2D6CYP2C19KDM4E | |
| Hydrochloric Acid SCHEMBL29651421 | 0.99 | KCNH2 (1.00) | KCNH2CYP3A4CYP2D6CYP2C19KDM4E | |
| Hydrochloric Acid SCHEMBL9444378 | 0.99 | KCNH2 (1.00) | KCNH2CYP3A4CYP2D6CYP2C19KDM4E | |
| Hydrochloric Acid SCHEMBL6375711 | 0.98 | KCNH2 (0.96) | KCNH2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL9444488 | 0.94 | KCNH2 (0.89) | KCNH2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL9444403 | 0.90 | KCNH2 (0.82) | KCNH2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL9444358 | 0.89 | KCNH2 (0.80) | KCNH2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL9444258 | 0.88 | KCNH2 (0.78) | KCNH2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL9444520 | 0.85 | KCNH2 (0.74) | KCNH2CYP3A4CYP2D6CYP2C19KDM4E | |
| Hydrochloric Acid SCHEMBL9444466 | 0.84 | KCNH2 (0.75) | KCNH2CYP3A4CYP2D6CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-13 | — | — | US | claimed |
| US-8399018-B2 | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2013-03-19 | — | — | US | claimed |
| EP-0235752-B1 | Piperidine derivative, pharmaceutical composition containing the same and use | EISAI CO LTD (JP) | 1993-11-18 | — | — | EP | claimed |
| US-4876262-A | ANTIARRHYTHMIA AGENTS | EISAI CO., LTD. (JP) | 1989-10-24 | — | — | US | claimed |
| EP-0235752-A2 | Piperidine derivative, pharmaceutical composition containing the same and use | Eisai Co., Ltd. (JP) | 1987-09-09 | — | — | EP | claimed |
| EP-3638673-B9 | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-20 | — | — | EP | disclosed |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-07 | — | — | US | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| EP-3512938-B1 | RECOMBINANT CARDIOMYOCYTES AND CARDIOMYOCYTE CELL LINES EXPRESSING HERG | UNIV ALBERTA (CA) | 2024-08-28 | — | — | EP | disclosed |
| EP-3638673-B1 | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-23 | — | — | US | disclosed |
| US-5877196-A | N- 4-(imidazolyl or pyrazolyl)phenyl(oxy, sulfinyl, sulfenyl or sulfonyl)alkyl!carboxamides, sulfonamides or phosphoramides having antiarrhythmic properties | AMERICAN CYANAMID COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0792873-A1 | N-(Phenoxyalkyl) carboxamides and their use as antiarrhythmic agents | American Cyanamid Company (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0235752-B1 | Piperidine derivative, pharmaceutical composition containing the same and use | EISAI CO LTD (JP) | 1993-11-18 | — | — | EP | disclosed |
| US-5179095-A | Antiarrhythmia agents | EISAI CO., LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
| US-5118689-A | Antiarrhythmia agents | EISAI CO., LTD. (JP) | 1992-06-02 | — | — | US | disclosed |
| US-4996215-A | Antiarrythmia agents | EISAI CO., LTD. (JP) | 1991-02-26 | — | — | US | disclosed |
| US-4876262-A | ANTIARRHYTHMIA AGENTS | EISAI CO., LTD. (JP) | 1989-10-24 | — | — | US | disclosed |
| EP-0235752-A2 | Piperidine derivative, pharmaceutical composition containing the same and use | Eisai Co., Ltd. (JP) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | TRPV1, ATP2A1, TRPM2 | KCNH2 56/4885CYP3A4 4499/4885CYP2D6 4439/4885 |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | KCNH2 4204/4885CYP3A4 4880/4885CYP2D6 4878/4885 |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | MKI67, MYLK2, MYH2 | KCNH2 4204/4885CYP3A4 4880/4885CYP2D6 4878/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | KCNH2 2334/4885CYP3A4 4486/4885CYP2D6 4391/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | KCNH2 2334/4885CYP3A4 4486/4885CYP2D6 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.